Protalix Biotherapeutics Inc
PLX
查看详细走势图
2.055USD
-0.085-3.97%
交易中 （美东）报价延迟15分钟
18.66M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.97%
5天
-3.97%
1月
-28.64%
6月
-4.86%
今年开始到现在
+14.17%
1年
-20.34%
查看详细走势图
TradingKey Protalix Biotherapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Protalix Biotherapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名86/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.00。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Protalix Biotherapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Protalix Biotherapeutics Inc亮点
亮点风险
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
业绩增长期
公司处于发展阶段，最新年度总收入52.74M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-25.45，处于3年历史低位
机构减仓
最新机构持股14.38M股，环比减少14.17%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值13.74K
活跃度降低
近期活跃度降低，过去20天平均换手率0.06
分析师目标
根据
1
位分析师
买入
评级
11.000
目标均价
+421.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Protalix Biotherapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Protalix Biotherapeutics Inc简介
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
公司代码PLX
公司Protalix Biotherapeutics Inc
CEOBashan (Dror)
网址https://protalix.com/
相关品种
